Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60

Clicks: 336
ID: 114114
1996
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The safety and immunogenicity of purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was evaluated in a randomized placebo-controlled, double-blind study of 64 healthy adults over age 60. Vaccination was well tolerated with no significant acute side-effects. Twenty-nine of 33 v …
Reference Key
ar1996vaccinesafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Falsey AR;Walsh EE;;
Journal Vaccine
Year 1996
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8961507
Keywords
vaccination National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male aged middle aged 80 and over Clinical Trial Randomized Controlled Trial Antibodies Double-Blind Method respiratory syncytial viruses / immunology* viral / blood viral vaccines / adverse effects* viral vaccines / immunology pmid:8961507 doi:10.1016/s0264-410x(96)00030-8 a r falsey e e walsh

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.